Publications
We introduce books, articles and other materials authored or co-authored by, and interviews with, ABE & PARTNERS attorneys.
-
"Avoiding disputes between university and industry, patent agreements are critical"
Source : Yomiuri Newspaper- Interview
- IP Disputes
- Life Science and Health Care
-
"Five minutes with…Takanori Abe, Abe & Partners"
Source : Managing Intellectual Property- Interview
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
-
"Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism"
Source : LSIPR- Article
- IP Disputes
- Life Science and Health Care
-
"Preliminary injunctions in pharmaceutical patent cases in Japan"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Preliminary injunctions in pharmaceutical patent cases in Japan"
Source : LSIPR- Article
- IP Disputes
- Life Science and Health Care
-
"Issues with the re-examination system having both a function of ensuring the safety of medicinal products and a function of data protection - The necessity to redesign the re-examination system from both pharmaceutical and IP perspectives -"
Source : NIHON KAJO Publishing Co., Ltd.- Book
- IP Disputes
- IP Transactions
- Life Science and Health Care
-
"Treatment of germ cell tumor and medical liability" (Co-author)
Source : Journal of Medical Law- Book
- Life Science and Health Care
-
"Regimen patents in Japan: LCM failures and successes"
Source : LSIPR- Article
- IP Disputes
- Life Science and Health Care
-
"Regimen patents: LCM failures and successes"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Generic should sue the Minister of Health, Labour and Welfare instead of filing a DJ action, says IP High Court"
Source : Managing Intellectual Property- Article
- IP Disputes
- Life Science and Health Care
-
"Generic should sue the Minister of Health, Labour and Welfare instead of filing a DJ action, says IP High Court"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Japan: DOE and cross-border infringement of a biologics process patent"
Source : LSIPR- Article
- IP Disputes
- Life Science and Health Care
-
"DOE and cross-border infringement of a biologics process patent"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Comparative analysis of demonstratives in patent litigation"
Source : Managing Intellectual Property- Article
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
-
"Comparative analysis of demonstratives in patent litigation"
- Newsletter
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
-
"How are IP, competition and healthcare law keeping up with lightning-speed innovation?"
Source : Research Outreach's video abstract- Article
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
- Antitrust/Competition
-
"The evolution of IP, competition, and healthcare law in line with lightning-speed innovation"
Source : Research Outreach- Interview
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
- Antitrust/Competition
-
"Medical Law,100 cases (3rd edition)"
Source : Co-author, Yuuhikaku- Book
- Life Science and Health Care
-
"Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox"
Source : Life Sciences Intellectual Property Review- Article
- IP Disputes
- Life Science and Health Care
- Antitrust/Competition
-
"Why the 'first penguin' of Pay for Delay has not come in Japan - Anatomy of a Japan Paradox -"
Source : ABA, Antitrust Law Section, Intellectual Property Committee, tidBITS- Article
- IP Disputes
- Life Science and Health Care
- Antitrust/Competition
-
"Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing"
Source : Life Sciences Intellectual Property Review- Article
- Life Science and Health Care
- Antitrust/Competition
-
"Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing"
Source : Springer l OA CC BY-NC-ND 4.0 International License- Book
- Life Science and Health Care
- Antitrust/Competition
-
"Asia patent trends in 2022: SEP rates, court changes and more"
Source : Managing Intellectual Property Magazine- Interview
- IP Disputes
- IP Transactions
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
- Cross-Border Transactions
- Antitrust/Competition
-
"Council discusses availability of iPS patents"
Source : Yomiuri Newspaper- Interview
- IP Disputes
- Life Science and Health Care
-
"A new drug pricing system reform proposal in Japan"
- Newsletter
- Life Science and Health Care
-
"A new drug pricing system reform proposal in Japan"
Source : Life Sciences Intellectual Property Review (2021’s most-read contributed articles)- Article
- Life Science and Health Care
-
"Will Authorised Biologics deter Biosimilars? - Utilising JFTC's expertise in drug pricing -"
Source : Fair Trade Magazine (August 2021)- Article
- Life Science and Health Care
- Antitrust/Competition
-
"Clinical trials for original drugs fall under experimental use exception"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Clinical trials for original drugs fall under experimental use exception"
Source : LSPN Connect- Article
- IP Disputes
- Life Science and Health Care
-
"A closer look at Japan’s desirable patent system in the era of COVID-19"
- Newsletter
- IP Disputes
- IP Transactions
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
- Cross-Border Transactions
-
"U.S. Patent Litigation Update : The Resurgence of Patent Trolls"
- Newsletter
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- International Disputes
-
"A closer look at Japan’s desirable patent system in the era of COVID-19"
Source : Managing Intellectual Property Magazine (SUMMER 2021)- Article
- IP Transactions
- Life Science and Health Care
- IT and Telecommunications
- Cross-Border Transactions
-
"Courts rule on likelihood of confusion in medical device case"
Source : Managing Intellectual Property Magazine (WINTER 2020)- Article
- IP Disputes
- Life Science and Health Care
-
"Courts rule on likelihood of confusion in medical device case"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Matsukiyo-Cocokara merger to create leading drugstore will benefit from regulatory changes"
Source : PaRR- Interview
- Life Science and Health Care
- M&A
- Antitrust/Competition
-
"Utilizing mediation in patent dispute"
Source : Nikkei Newspaper- Interview
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
- Antitrust/Competition
-
"Rituximab biosimilar patent infringement lawsuit"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Rituximab biosimilar patent infringement lawsuit"
Source : LSPN Connect- Article
- IP Disputes
- Life Science and Health Care
-
"The Broad Institute’s CRISPR-Cas9 patents"
Source : LSPN Connect- Article
- IP Disputes
- Life Science and Health Care
-
"The Broad Institute’s CRISPR-Cas9 patents"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"How was Japanese patent litigation reformed?"
Source : Managing Intellectual Property Magazine (WINTER 2020)- Article
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
-
"How was Japanese patent litigation reformed"
- Newsletter
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
-
"Why reverse payment is unlikely to arise in Japan?"
Source : Fair Trade magazine (November 2020)- Article
- IP Disputes
- Life Science and Health Care
- Antitrust/Competition
-
"Inventor of anti-PD-L1 antibody patent"
Source : LSPN Connect- Article
- IP Disputes
- Life Science and Health Care
-
"Inventor of anti-PD-L1 antibody patent"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"New IP Mediation Proceedings"
- Newsletter
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
-
"Antibodies: Should they be defined by function or sequence?"
Source : Managing Intellectual Property Magazine(Online)- Article
- IP Disputes
- Life Science and Health Care
-
"Antibodies: Should they be defined by function or sequence?"
- Newsletter
- IP Disputes
- Life Science and Health Care
-
"Japan suffers from trade secret infringement"
- Newsletter
- IP Disputes
- Life Science and Health Care
- IT and Telecommunications
